Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

Mountzios, Giannis; Sun, Longhua; Chul Cho, Byoung; Demırcı, Umut; Baka, Sofia; Gümüş, Mahmut; Lugini, Antonio; Zhu, Bo; Yu, Yan; Korantzis, Ippokratis; Han, Ji‐Youn; Ciuleanu, Tudor–Eliade; Ahn, Myung‐Ju; Rocha, Pedro; Mazières, Julien; C. M. Lau, Sally; Schüler, Martin; Blackhall, Fiona; Yoshida, Tatsuya; K. Owonikoko, Taofeek; Paz‐Ares, Luis; Jiang, Tony; Hamidi, Ali; Maria Gauto, Diana; Recondo, Gonzálo; M. Rudin, Charles

doi:10.1056/nejmoa2502099

Public

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

Published in New England Journal of Medicine • Jun 2, 2025

Authors:

Giannis Mountzios

Longhua Sun

Byoung Chul Cho

Abstract

BACKGROUND: Tarlatamab, a bispecific delta-like ligand 3-directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer. Whether tarlatamab is more effective than chemotherapy in the treatment of patients whose small-...

Subject

Platinum

Chemotherapy

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!